St. Louis Breast Cancer Tissue Registry

圣路易斯乳腺癌组织登记处是过去9年合作的四个机构之一。 多年来，形成了国家癌症研究所的合作乳腺癌组织资源。使命 这一组的组织，评估，维护和分配档案乳腺癌 标本加上临床治疗，结果和肿瘤病理学的详细数据，以促进 新的诊断和预后肿瘤标志物的研究。肿瘤标志物的意义 表达数据通过从癌症登记记录中编辑的大量病例数据而大大增强， 临床图表、病理学报告和>5年的复发和生命状态患者随访。与更多 CBCTR提供了来自美国4个地理和种族不同地区的9000多个标本， 一个独特的集合，代表社区医疗中心的患者群体，用于评估乳腺癌 单个医疗机构或生物技术研究人员不容易获得的癌症标志物 企业CBCTR机构的PI的综合专业知识包括临床肿瘤学、乳腺癌 组织病理学、临床实验室操作、临床试验和共享资源&癌症研究 laboratories.持续审核临床数据和肿瘤分类，开发新组织 筛选技术（组织微阵列），对应用进行重要的科学和统计审查， 的资源标本，和适度的服务费进一步增加了这个资源的特殊价值 在许多研究的支持。在接下来的三年里，我们将继续履行 合作协议的职责包括：1）与CBCTR的所有成员合作， 协调结构，为研究人员提供现有的组织和数据，2）与所有CBCTR成员合作， 根据NCI的建议，为组织微阵列的设计和构建提供样本， 研究评估小组（REP），3）继续监测、更新和与IMS中心沟通 数据库，收集与我们病例相关的数据，4）与所有研究中心、NCI、IMS和REP合作 成员实现NCI的目标，并向癌症研究界宣传这一资源，以及5） 计划其他乳腺癌组织（存档或新鲜/冷冻）的采集和数据收集， 补充我们有限的收藏

The St.Louis Breast Cancer Tissue Registry is one of four institutions that have collaborated for the past 9 years to form the Cooperative Breast Cancer Tissue Resource of the National Cancer Institute. The mission of this group has been the organization, evaluation, maintenance, and distribution of archival breast cancer specimens coupled with detailed data on clinical treatment, outcome, and tumor pathology to facilitate research investigations of new diagnostic and prognostic tumor markers. The significance of tumor marker expression data is greatly enhanced by the extensive case data compiled from cancer registry records, clinical charts, pathology reports, and >5 years patient follow-up for recurrence and vital status. With more than 9000 specimens from 4, geographically and ethnically, diverse regions of the US, the CBCTR provides a unique collection, representative of community medical center patient populations, for evaluation of breast cancer markers that is not readily available to investigators at single medical institutions or biotechnology companies. The combined expertise of the Pl's at the CBCTR institutions include clinical oncology, breast tissue pathology, clinical laboratory operations, clinical trials, and shared resource & cancer research laboratories. Continuing audits of clinical data and tumor classification, development of new tissue screening technologies (tissue microarrays), significant scientific and statistical review of applications for use of the Resource specimens, and moderate service fees further add to the exceptional value of this Resource in the support of many research studies. Over the next 3 year period we will continue to fulfill the responsibilities of a cooperative agreement including 1) work with all members of the CBCTR in a coordinated structure to provide existing tissue and data to researchers, 2) work with all CBCTR members to provide specimens for design and construction of Tissue Microarrays as recommended by the NCI and Research Evaluation Panel (REP), 3) continue to monitor, update, and communicate, with the IMS Central Database, the collection of data linked to our cases, 4) cooperate with all sites, NCI, IMS, and REP members to achieve NCI goals and to publicize this Resource to the cancer research community, and 5) to plan the acquisition and data collection for additional breast cancer tissues, either archival or fresh/frozen, to replenish our finite collection.